RAPT Therapeutics (NASDAQ: RAPT)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-10 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.680 | -0.690 | -0.0100 | ||||
REV | 220.000K | 641.000K | 421.000K |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of RAPT Therapeutics (NASDAQ: RAPT) through any online brokerage.
Other companies in RAPT Therapeutics’s space includes: IDEAYA Biosciences (NASDAQ:IDYA), Kezar Life Sciences (NASDAQ:KZR), Cogent Biosciences (NASDAQ:COGT), Centessa Pharmaceuticals (NASDAQ:CNTA) and Brickell Biotech (NASDAQ:BBI).
The latest price target for RAPT Therapeutics (NASDAQ: RAPT) was reported by HC Wainwright & Co. on Thursday, June 23, 2022. The analyst firm set a price target for 50.00 expecting RAPT to rise to within 12 months (a possible 171.00% upside). 7 analyst firms have reported ratings in the last year.
The stock price for RAPT Therapeutics (NASDAQ: RAPT) is $18.45 last updated Today at July 5, 2022, 4:50 PM UTC.
There are no upcoming dividends for RAPT Therapeutics.
RAPT Therapeutics’s Q2 earnings are confirmed for Wednesday, August 10, 2022.
There is no upcoming split for RAPT Therapeutics.
RAPT Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.